Abstract
The prognosis for patients with distant-organ metastatic cervical cancer (CC) is poor owing to the lack of effective treatment modalities. We present a case of CC with lung metastasis that achieved partial remission of the cervical mass after two cycles of chemotherapy, while the pulmonary nodules remained stable. Moreover, the level of the tumor marker squamous cell carcinoma antigen was slightly higher than before. The patient was recommended to receive pelvic concurrent chemoradiotherapy combined with camrelizumab. Remarkably, after undergoing 16 cycles of immunotherapy, the patient’s primary cervical mass and pulmonary nodules were in complete remission, and the tumor marker had returned to normal levels. This inspiring case demonstrates that a combination of chemo-/radio-/immunotherapy can be effective in treating lung metastatic CC and can also enhance the abscopal effect.
Plain language summary
Checkpoint inhibitors are a type of treatment for cancer. They can be used alone or together with chemotherapy, and they have recently been approved for the treatment of advanced and recurrent cervical cancer. This article looks at how these checkpoint inhibitors can be used with another treatment called chemoradiotherapy. This treatment combines chemotherapy and radiation therapy. This is to see whether using checkpoint inhibitors with chemoradiotherapy can help even more. Here we report a patient with cervical cancer that had spread to the lungs. They received treatment with chemotherapy, radiation therapy and checkpoint inhibitors. The good news is that the cancer went away completely after this treatment. The patient continued to receive checkpoint inhibitors to keep the cancer from coming back. It has been 26 months, and the patient is still cancer-free. This case shows that using checkpoint inhibitors with chemoradiotherapy can be a very effective treatment for cervical cancer that has spread to other parts of the body.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob. Health 8(2), e191–e203 (2020). • An introduction to the epidemiology of cervical cancer.
- 2. . Cancer of the cervix uteri. Int. J. Gynaecol. Obstet. 143(Suppl. 2), 22–36 (2018).
- 3. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy. Anticancer Agents Med. Chem. 14(2), 190–203 (2014).
- 4. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 37(17), 1470–1478 (2019).
- 5. . Role of immunotherapy in the management of locally advanced and recurrent/metastatic cervical cancer. J. Natl Compr. Canc. Netw. 17(1), 91–97 (2019).
- 6. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N. Engl. J. Med. 385(20), 1856–1867 (2021). •• Important review of pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer.
- 7. Scientific Writing in Health and Medicine (SWIHM). www.care-statement.org/
- 8. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 370(8), 734–743 (2014). • Pembrolizumab showed favorable results in a case of advanced cervical cancer.
- 9. . Hyperprogressive disease in advanced cancer patients with liver metastasis treated with PD-1 inhibitors: two case reports. Ann. Transl. Med. 8(17), 1100 (2020).
- 10. . Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod. Pathol. 28(12), 1594–1602 (2015).
- 11. Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch. Pathol. Lab. Med. 140(11), 1243–1249 (2016).
- 12. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. J. Immunother Cancer 9(5), e002223 (2021).
- 13. US Food and Drug Administration. FDA approves pembrolizumab combination for the first-line treatment of cervical cancer (2021). www.fda.gov/drugs/resources-information-approved-drugs/fdaapproves-pembrolizumab-combination-first-line-treatment-cervical-cancer • US FDA-approved pembrolizumab plus chemotherapy with or without bevacizumab for the first-line treatment of cervical cancer.
- 14. . Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 39(8), 644–655 (2018).
- 15. Abscopal effect of radiation on toruliform para-aortic lymph node metastases of advanced uterine cervical carcinoma–a case report. Anticancer Res. 27(1b), 499–503 (2007).
- 16. Induction of micronuclei in cervical cancer treated with radiotherapy. J. Pers. Med. 10(3), 110 (2020).
- 17. Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. Brachytherapy 16(6), 1246–1251 (2017).
- 18. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mabs and are dependent on CD8 T cells and crosspriming. Cancer Res. 76(20), 5994–6005 (2016).
- 19. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. J. Natl. Compr. Canc. Netw. 18(6), 660–666 (2020).
- 20. . The combined use of chemotherapy and radiotherapy with PD-1 inhibitor, pembrolizumab, in advanced cervical cancer: a case report. Onco Targets Ther. 13, 4465–4471 (2020).
- 21. . Pembrolizumab in recurrent advanced cervical squamous carcinoma. Immunotherapy 9(6), 467–470 (2017). • Pembrolizumab showed favorable results in a case of advanced cervical cancer.
- 22. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078–2092 (2018).
- 23. AstraZeneca. Update on CALLA phase III trial of concurrent use of Imfinzi and chemoradiotherapy in locally advanced cervical cancer. Press release (2022). https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-calla-phase-iii-trial-for-imfinzi.html •• Important phase III trial of immunotherapy plus chemoradiotherapy in locally advanced cervical cancer.
- 24. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. Int. J. Gynecol. Cancer 30(5), 701–704 (2020). •• Important trial of immunotherapy plus chemoradiotherapy for node-positive locally advanced cervical cancer.
- 25. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. Lancet Oncol. 24(4), 371–382 (2023).
- 26. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT). Clin. Cancer Res. 27(12), 3351–3359 (2021).
- 27. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur. J. Cancer 144, 232–241 (2021).
- 28. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study. Oncoimmunology 10(1), 1971418 (2021).
- 29. . Advances in immunotherapy for cervical cancer. Curr. Opin. Oncol. 32(5), 481–487 (2020). •• Review on the role of immunotherapy in cervical cancer.
- 30. . Top advances of the year: cervical cancer. Cancer 129(5), 657–663 (2023). •• Review on advances in cervical cancer.